An Infectious Diseases Perspective on Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children

J Pediatric Infect Dis Soc. 2019 Dec 27;8(6):580-584. doi: 10.1093/jpids/piz062.

Abstract

Fecal microbiota transplantation (FMT) is efficacious for treatment of recurrent Clostridioides difficile infections (rCDIs). Pediatric experience with FMT for rCDIs is increasing, particularly at large centers. While retrospective studies suggest that FMT is generally safe in the short term, particularly in immunocompetent patients and with rigorous donor screening, additional large prospective studies are needed. This particularly includes those at high risk for infectious complications, such as immunocompromised hosts. Further, long-term implications of altering the intestinal microbiome with FMT are not well understood. The role of FMT in children, particularly in high-risk patients, will require continual reexamination with future availability of pediatric safety and efficacy data. This review summarizes key points for infectious diseases physicians to consider when evaluating a child for FMT.

Keywords: Clostridioides difficile; Clostridium difficile; fecal microbiota transplantation; safety; screening.

Publication types

  • Review

MeSH terms

  • Clostridioides difficile
  • Clostridium Infections / etiology*
  • Clostridium Infections / therapy*
  • Communicable Diseases / etiology*
  • Fecal Microbiota Transplantation / methods*
  • Gastrointestinal Microbiome
  • Humans
  • Immunocompromised Host
  • Patient Safety
  • Prospective Studies
  • Retrospective Studies
  • Treatment Outcome